Related references
Note: Only part of the references are listed.Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons
Rikke Fredslund Andersen et al.
CLINICA CHIMICA ACTA (2015)
Circulating Tumor DNA as a Liquid Biopsy for Cancer
Ellen Heitzer et al.
CLINICAL CHEMISTRY (2015)
Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?
M. Ignatiadis et al.
ANNALS OF ONCOLOGY (2014)
Quantification of epigenetic biomarkers: an evaluation of established and emerging methods for DNA methylation analysis
Nicholas Redshaw et al.
BMC GENOMICS (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Alain R. Thierry et al.
NATURE MEDICINE (2014)
Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island
Reinhold Wasserkort et al.
BMC CANCER (2013)
Epigenetic alteration: new insights moving from tissue to plasma - the example of PCDH10 promoter methylation in colorectal cancer
E. Danese et al.
BRITISH JOURNAL OF CANCER (2013)
Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients
Valerie Taly et al.
CLINICAL CHEMISTRY (2013)
Multiple KRAS Mutations in Pancreatic Adenocarcinoma: Molecular Features of Neoplastic Clones Indicate the Selection of Divergent Populations of Tumor Cells
Michela Visani et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2013)
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients
Grigoriy A. Yanus et al.
MEDICAL ONCOLOGY (2013)
Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load
Florent Mouliere et al.
TRANSLATIONAL ONCOLOGY (2013)
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
D. Gonzalez de Castro et al.
BRITISH JOURNAL OF CANCER (2012)
Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
Karen-Lise Garm Spindler et al.
CLINICAL CANCER RESEARCH (2012)
Evolution of the cancer genome
Lucy R. Yates et al.
NATURE REVIEWS GENETICS (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Stromal cells do not share KRAS mutations that the epithelial component harbors in colorectal carcinomas
Huseyin Baloglu et al.
CANCER LETTERS (2011)
High Fragmentation Characterizes Tumour-Derived Circulating DNA
Florent Mouliere et al.
PLOS ONE (2011)
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
Stephen B. Edge et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
V. Deschoolmeester et al.
BRITISH JOURNAL OF CANCER (2010)
Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer
Qiong He et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Cell-free DNA in the blood as a solid tumor biomarker-A critical appraisal of the literature
Klaus Jung et al.
CLINICA CHIMICA ACTA (2010)
A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples
Gillian Ellison et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
Li-Chen Yen et al.
CLINICAL CANCER RESEARCH (2009)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay
Robert Gruetzmann et al.
PLOS ONE (2008)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up
BM Ryan et al.
GUT (2003)
Share Paper
